Genetic and biological drivers of prostate cancer disparities in Black men
Black men with prostate cancer have historically had worse outcomes than white men with
prostate cancer. The causes of this disparity in outcomes are multi-factorial, but a potential …
prostate cancer. The causes of this disparity in outcomes are multi-factorial, but a potential …
Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment
The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …
prostate cancer (mHSPC) has been built on successes in therapy development for …
Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers
Importance Targeted therapies based on underlying tumor genomic susceptible alterations
have been approved for patients with metastatic prostate cancer (mPC) and advanced …
have been approved for patients with metastatic prostate cancer (mPC) and advanced …
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
A Chehrazi-Raffle, H Tukachinsky, E Toye… - Clinical Cancer …, 2023 - AACR
Purpose: Alterations in BRAF have been reported in 3% to 5% of prostate cancer, although
further characterization is lacking. Here, we describe the nature of BRAF alterations in …
further characterization is lacking. Here, we describe the nature of BRAF alterations in …
Genetic and genomic testing for prostate cancer: beyond DNA repair
Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian
framework to evaluate efficacy within predefined biomarker signatures across systemic …
framework to evaluate efficacy within predefined biomarker signatures across systemic …
De novo metastatic prostate cancer: Are we moving toward a personalized treatment?
C Piombino, M Oltrecolli, E Tonni, M Pirola, R Matranga… - Cancers, 2023 - mdpi.com
Simple Summary De novo metastatic hormone-sensitive prostate cancer usually has a
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
Ubiquitin E3 ligase SPOP is a host negative regulator of enterovirus 71-encoded 2A protease
L Zang, X Yang, Y Chen, F Huang, Y Yuan… - Journal of …, 2023 - Am Soc Microbiol
ABSTRACT The 2A protease (2Apro) encoded by enterovirus 71 (EV71) serves as an
accessory protein with significant involvement in the regulation of EV71 infection and viral …
accessory protein with significant involvement in the regulation of EV71 infection and viral …
Cardio-oncology in advanced prostate cancer
Treatment intensification with androgen deprivation therapy (ADT) and androgen receptor
pathway inhibitors (ARPi) have led to improved survival in advanced prostate cancer …
pathway inhibitors (ARPi) have led to improved survival in advanced prostate cancer …
Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy
AV Serritella, M Hussain - Current Treatment Options in Oncology, 2024 - Springer
Opinion Statement Treatment for metastatic hormone–sensitive prostate cancer has
undergone significant evolution in recent years, leading to substantial improvements in …
undergone significant evolution in recent years, leading to substantial improvements in …